Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a local, multicenter, randomized, active comparator, double-blind, parallel group
study with extension will be conducted to evaluate the efficacy and safety of celecoxib
versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.